US-based medical device developer Prescient Surgical raised $10m yesterday in a series B round that featured Stanford University’s Standford-StartX Fund.
Baxter Ventures, the strategic investment unit of medical products maker Baxter International, led the round, while Summation Health Ventures, the venture capital fund formed by healthcare systems Cedars-Sinai and MemorialCare and private equity firm CWC HealthTech Advisors also participated.
Prescient Surgical designs and develops tools and technologies to combat the sources of surgical site infection. Its flagship product, CleanCision, removes contamination and fights potentially harmful bacteria during surgical procedures.
Prescient Surgical will use the funding to accelerate the availability of CleanCision, which is commercially available in the US and approved for use in Europe.
In October 2014, Prescient Surgical raised $6m in a series A round according to a regulatory filing. The company has not disclosed any further details but lists Summation, CWC HealthTech Advisors and Standford-StartX Fund as original investors.
Jonathan Coe, CEO at Prescient Surgical, said: “We brought together a world class mix of venture, hospital, and corporate strategic investors in support of our mission to help hospitals achieve zero preventable infections.
“CleanCision is emerging as a key technology to advance the standard of care for surgical patients.”
– A version of this story first appeared on our sister site, Global Corporate Venturing.

US-based medical device developer Prescient Surgical raised $10m yesterday in a series B round led by Baxter Ventures, the strategic investment unit of medical products maker Baxter International.

Summation Health Ventures, the venture capital fund formed by healthcare systems Cedars-Sinai and MemorialCare, private equity firm CWC HealthTech Advisors and Stanford University’s Standford-StartX Fund also joined the round.

Prescient Surgical designs and develops tools and technologies to combat the sources of surgical site infection. Its flagship product, CleanCision, removes contamination and fights potentially harmful bacteria during surgical procedures.

Prescient Surgical will use the funding to accelerate the availability of CleanCision, which is commercially available in the US and approved for use in Europe.

In October 2014, Prescient Surgical raised $6m in a series A round according to a regulatory filing. The company has not disclosed any further details but lists Summation, CWC HealthTech Advisors and Standford-StartX Fund as original investors.

Jonathan Coe, CEO at Prescient Surgical, said: “We brought together a world class mix of venture, hospital, and corporate strategic investors in support of our mission to help hospitals achieve zero preventable infections.

“CleanCision is emerging as a key technology to advance the standard of care for surgical patients.”